Systemic antibiotic agents

Dermatologic Clinics

Volumn 19, Issue 1, 2001, Pages 1-21

  Sadick, Neil S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; FOLIC ACID ANTAGONIST; GENTAMICIN; IMIPENEM; KANAMYCIN; MACROLIDE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; NEOMYCIN; NETILMICIN; NITROFURAN DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; QUINUPRISTIN; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; SPECTINOMYCIN; STREPTOMYCIN; SULFADIAZINE; SULFADOXINE; SULFAFURAZOLE; SULFAMETHIZOLE; SULFAMETHOXAZOLE; SULFAPYRIDINE; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG DOSE; DRUG METABOLISM; DRUG STRUCTURE; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0035166681     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70226-6     Document Type: Article

References (190)

1. The pharmacokinetics and tissue penetration of norfloxacin
2. Comparison of the effects of the new azalide antibiotic azithromycin, and erythromycin estolate on rat liver cytochrome P- 450
3. Doxycycline induced esophagitis
4. Nail and scleral pigmentation induced by minocycline
5. Aztreonam. AHFS Drug Information 95
6. Clindamycin. AHFS Drug Information 95
7. Imipenem. AHFS Drug information 95
8. Tetracycline. AHFS Drug Information 95
9. Effects of long-term rifampin administration on primary biliary cirrhosis
10. The new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin an rooxithromycin
11. Clinical efficacy and tolerance of augmentin in soft tissue infection
12. Aztreonam: Antibacterial activity, β-lactamase stability, and interpretive standards and quality control guidelines for disk diffusion susceptability tests
13. Antimicrobial agents implicated in Clostridium difficile toxin associated diarrhea or colitis
14. Imipenem: First of a new class of betalactam antibiotic
15. Development of β-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis
16. Mycobacterium avium complex infection and AIDS: Advances in theory and practice
17. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination
18. Pharmacokinetics of quinupristin/dalfopristin in laboratory animals and humans
19. The treatment of bullous pemphigoid with tetracycline and nicotinamide: A preliminary report
20. Drug induced toxic pustulodema
21. Antibiotiques en pathologie cutanee
22. Update on rifampin drug interactions
23. In vitro activity of RO 15-8074, RO 19-5247, A56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis
24. The monobactams
25. Rifabutin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy
26. Dirithromycin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy
27. Study of the effects of ticarcillin on blood coagulation and platelet function
28. Piperacillin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
29. Disulfiram-like reactions to β-lactams
30. In vitro activity of aztreonam in combination with newer β-lactams and amikacin against multiply resistant bacilli
31. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin
32. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin
33. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: A review of 13 cases
34. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria
35. Trimethoprim-sulfamethoxazole
36. In vitro susceptibility of mycobacteria to ciprofloxacin
37. Antibiotic formulary section
38. Comparative activities of newer β-lactam agents against members of the Bacteroides fragilis group
39. Gynecomastia in association with minocycline
40. Clindamycin: A review of fifteen years of experience
41. Beta-lactam antibiotics (second of two parts)
42. The pharmacokinetics of meropenem
43. The in vitro activity of CP-62,993 against Haemophilus influenzae, Branhamaella catarrhali, staphylococci, and streptococci
44. Tetracycline induced pancreatitis
45. Seizure propensity with imipenem
46. Antimicrobial agents for the dermatologist: II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfa methoxazole and clindamycin
47. Anti-microbial agents for the dermatologist: I. Lactam antibiotics and related compounds
48. Influence of subsalicylate bismuth on absorption of doxycycline
49. Clindamycin and metronidazole
50. Treatment of skin and soft tissue infections with imipenem/cilastatin
51. Cephalexin - A new oral cephalosporin: Clinical evaluation in sixty-three patients
52. Pharmacokinetics of new oral cephalosporins, including a new carbacephem
53. Pyrimethamine-clarithromycin combination for therapy of acute toxoplasma encephalitis in patients with AIDS
54. Pharmacokinetics of quinolones in renal insufficiency
55. Antibacterial activity of quinupristin/dalfopristin rationale for clinical use
56. The quinolones: An overview of their pharmacology
57. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of anti-diuretic hormone
58. Treatment of Mycobacterium chelonae induced skin infection with clarithromycin
59. Hemolytic anemia associated with cephalothin
60. The effect of rifampicin on rhinoscleroma: An electron microscopic study
61. Effect of probenecid on the pharmacokinetics of piperacillin and tazobactam in healthy volunteers
62. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice
63. Binding of monobactams to penicillin binding proteins of Escherichia coli and Staphylococcus aureus: Relation to antibacterial activity
64. Modes of action of aztreonam
65. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics
66. Aeromonas hydrophilia infections of skin and soft tissue: Report of 11 cases and review
67. Goldberg MD: The cephalosporins
68. Outpatient therapy of bite wounds: Demographic data, bacteriology and a prospective, randomized trial of amoxicillin-clavulanic acid versus penicillin dicloxacillin
69. Goodgame RW: Understanding intestinal spore-forming protozoa: Cryptosporidia, microsporidia, Isospora, and Cyclospora
70. Once-daily ceftriaxone for skin and soft tissue infections
71. Infectious complications of erythrodermic psoriasis
72. Adverse effects of rifampin
73. Minocycline induced cells mediated hypersensitivity pneumonitis
74. Cephalosporin anti-microbial agents and related compounds
75. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans
76. Azithromycin and terfenadine: Lack of drug interaction
77. Imipenem
78. Fluoroquinolone antimicrobial agents
79. The role of fluoroquinolones in sexually transmitted diseases
80. Phototoxicity and phototoxicity and photoallergenicity of quinolones in guinea pigs
81. Addition of rifampicin to conventional therapy for recurrent furunculosis
82. Disturbing susceptibility pattern for ciprofloxacin
83. Ampicillin-sulbactam and ticarcillin-clavulanic acid: A comparison of their in vitro activity and review of their clinical efficacy
84. Clinical efficacy of dirithromycin in pneumonia
85. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis
86. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia
87. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients
88. The cephalosporins in dermatologic practice
89. AIDS exacerbation psoriasis
90. Adverse reaction reporting of interactions between warfarin and fluoroquinolones
91. Review of the in vitro spectrum of activity of imipenem
92. Imipenem/cilastatin in the treatment of intra-abdominal infections: A review worldwide experience
93. Possible interaction between ciprofloxacin and warfarin
94. Black tongue associated with minocycline therapy
95. In vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria
96. Tetracyclines
97. Prevention of recurrent staphylococcal skin infections with low dose oral clindamycin therapy
98. Serious adverse reactions induced by minocycline: Report of 13 patients and review of the literature
99. Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species
100. Blue black pigmentation of the legs associated with perfloxacin therapy
101. Evidence for streptococcal superantigen driven process in acute guttate psoriasis
102. Antigenicity and cross reactivity of penicillins and cephalosporins
103. Contribution of chromosomal beta-lactamase to beta-lactam resistance in enterobacteria
104. Cytochrome P450 complex formation by dirithromycin and other macrolides in rat and human lives
105. Ceftriax-one-induced cholelithiasis
106. Photoreactions with a fluoroquinolone antimicrobial: Evening vs morning dosing
107. Azithromycin compared with amoxicillin in the treatment of erythema migrans: A double-blind, randomized controlled trial
108. Effects of beta-lactamase-medicated antimicrobial resistance: The role of beta-lactamase inhibitors
109. Mycetoma
110. Antibiotic therapy for cat-scratch disease: Clinical study of the therapeutic outcome in 268 patients and a review of the literature
111. Minocycline related lupus
112. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clindamycin
113. The new cephalosporins
114. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease
115. Aztreonam: The first monobactam
116. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases
117. The new beta-lactamase-stable cephalosporins
118. Clinical pharmacokinetics of the newer antimicrobial 4-quinolones
119. Interference of iron with the absorption of tetracyclines in man
120. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized multi-centered studies of quinupristin/dalfopristin vs. cefazolin, oxacillin or vancomycin
121. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections
122. Side effects of cephalosporins
123. Carbapenems
124. Pharmacokinetics of imipenem in healthy volunteers
125. Safety and efficacy of clarithromycin (C) compared to erythromycin (E) in the treatment (tx) of bacterial skin or skin structure infections (SSSIs)
126. Rifabutin (Ansamycin LM427): A new rifamycin-S derivative for the treatment of mycobacterial diseases
127. Clarithromycin in the treatment of skin and skin structure infections: Two multicenter clinical studies
128. Systemic antimicrobial therapy for skin and skin structure infections: Comparison of fleroxacin and ceftazidime
129. Cephalosporin therapy in dermatologic practice
130. The quinolones and dermatologic practice
131. Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages
132. Clarithromycin, a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential
133. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial
134. Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV patients
135. Clarithromycin and azithromycin: New macrolide antibiotics
136. Lomefloxacin photosensitivity
137. Open trial of oral fleroxacin vs amoxicillin/clavulante in the treatment of infections of skin and soft tissue
138. Rhodococcus equi: An animal and human pathogen
139. Dietary constituents and rifampicin absorption
140. Clinical experience with cefazolin and other cephalosporins in bacterial endocarditis
141. A comparative of efficacy of drug regimens in skin tuberculosis
142. Oral antibiotics therapy of dermatologic conditions
143. Spectrum and mode of action of azithromycin (CP-662,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
144. Cefaclor and serum sickness-like reactions
145. Imipenem and aztreonam: Current role in antimicrobial therapy
146. Trimethoprim-sulfameth-oxazole
147. Safety and tolerability of quinupristin/dalfopristin: Administration guidelines
148. Oral ofloxacin: A critical review of the new drug application
149. Hematologic complications associated with β-lactam antibiotics
150. Immediate hypersensitivity reactions to beta-lactam antibiotics
151. Immediate hypersensitivity reactions to beta-lactam antibiotics. UCLA Conference
152. Photosensitizing potential of oofloxacin
153. Azithromycin and clarithromycin
154. Clinical experience with aztreonam in the treatment of gram-negative bacteremia
155. Beta-lactamase inhibitor combinations
156. Comparative in vitro activity of SM7338: A new carbapenem antimicrobial agent
157. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North America centers
158. Renal disease and the metabolic effects of tetracycline
159. Safety profile of dirithromycin
160. Trimetho prim-sulfamethoxazole therapy for nocardia infections
161. The adverse effects of fluoroquinolones
162. Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections
163. Multicenter positive randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and cotrimoxazole for treatment of severe meliodosis
164. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: Case report and review of the literature
165. Tetracyclines and chloramphenicol
166. Amoxicillin/clavulanic acid: The effect of probenecid
167. Effect of food on the bioavailability and tolerance of clavulanic acid/amoxicillin combination
168. Treatment of the early manifestations of Lyme disease
169. Drug interactions with fluoroquinolones
170. Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination
171. The new macrolide antibiotics: Azithromycin and clarithromycin
172. Clarithromycin: A review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles
173. In vitro antimicrobial activity of aztreoman alone and in combination against bacterial isolates from pediatric patients
174. Quinolones
175. Clinical pharmacology of aztreonam in healthy recipients and patients: A review
176. Oral bioavailability of the monobactam aztreonam (SQ 26,776) in healthy subjects
177. Aztreonam: The first monobactam
178. Minocycline induced Sweet's syndrome
179. Rifampin: Spectrum of antibacterial activity
180. Rifampin in dermatology
181. Rifampin therapy in severe forms of psoriasis
182. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in treatment of psoriasis
183. Trimethoprim-sulfamethoxazole associated acute febrile neutrophilic dermatosis: Case report and review of drug induced Sweet's syndrome
184. Susceptibility of Mycobacterium marium to tetracyclines and aminoglycosides
185. Effect of rifampin on nasal carrier of coagulase-positive staphylococci
186. The influence of quinolone derivatives on theophylline clearance
187. Fluoroquinolone antimicrobial agents
188. Azithromycin for cerebral toxoplasmosis in AIDS
189. Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone